跳转至内容
Merck
CN

SRP3160

sRank Receptor human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

别名:

ODAR (osteoclast differentiation and activation receptor), TNFRSF11A, TRANCE Receptor

登录 查看组织和合同定价。

选择尺寸

变更视图

关于此项目

NACRES:
NA.32
UNSPSC Code:
12352200
Form:
lyophilized
Assay:
≥98% (HPLC), ≥98% (SDS-PAGE)
Biological source:
human
Recombinant:
expressed in E. coli
Mol wt:
19.3 kDa
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助


biological source

human

recombinant

expressed in E. coli

assay

≥98% (HPLC), ≥98% (SDS-PAGE)

form

lyophilized

potency

30-50 ng/mL ED50

mol wt

19.3 kDa

packaging

pkg of 100 μg

technique(s)

cell culture | mammalian: suitable

impurities

<0.1 EU/μg endotoxin, tested

color

white

UniProt accession no.

shipped in

wet ice

storage temp.

−20°C

Gene Information

human ... TNFRSF11A(8792)

General description

Soluble receptor activator of nuclear factor-κB (sRANK) also known as TNF receptor superfamily member 11a (TNFRSF11A), is encoded by the gene mapped to human chromosome 18. The encoded protein belongs to the tumor necrosis factor (TNF) receptor superfamily. RANK is widely expressed in variety of tissues, including skeletal muscle, thymus, liver, colon, small intestine, adrenal gland, osteoclast, mammary gland epithelial cells, prostate and pancreas. Recombinant human sRANK receptor is a 19.3kDa polypeptide containing the TNFR homologous cysteine rich portion of the extracellular domain of RANK receptor (175 amino acid residues).

Biochem/physiol Actions

Soluble receptor activator of nuclear factor-κB (sRANK) plays a vital role in bone remodeling and fracture repair. Alterations in the RANK signaling increase the risk of susceptibility to expansile osteolysis and Paget disease of bone (PDB2). In addition, mutation of the gene coding for RANK/RANKL/OPG has also been observed in various skeletal disorders such as osteoporosis, glucocorticoid-induced bone loss, multiple myeloma, and rheumatoid arthritis. Binding of RANKL to its receptor RANK triggers the formation and differentiation of osteoclasts with the help of various transcription factors involved in modulation of osteoclastogenesis. RANK/RANKL/OPG might act as a potent therapeutic target for bone diseases.

Physical form

Lyophilized from 10 mM Sodium Phosphate, pH 7.2.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

MQIAPPCTSE KHYEHLGRCC NKCEPGKYMS SKCTTTSDSV CLPCGPDEYL DSWNEEDKCL LHKVCDTGKA LVAVVAGNST TPRRCACTAG YHWSQDCECC RRNTECAPGL GAQHPLQLNK DTVCKPCLAG YFSDAFSSTD KCRPWTNCTF LGKRVEHHGT EKSDAVCSSS LPARK


存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

法规信息

新产品

此项目有



历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库



CLINICAL Review #: the role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications.
Vega D
The Journal of Clinical Endocrinology and Metabolism, 92(12), 4514-4521 (2007)
RANKL-RANK signaling in osteoclastogenesis and bone disease.
Wada T
Trends in Molecular Medicine, 12(1), 17-25 (2006)
Mutations in TNFRSF11A, affecting the signal peptide of RANK, cause familial expansile osteolysis.
Hughes AE
Nature Genetics, 24(1), 45-48 (2000)



全球贸易项目编号

货号GTIN
SRP3160-100UG04061837210235